Table 3.
Multivariate analysis of factors predicting recurrence-free survival
| Factors | Univariate (P-value) |
Multivariate (P-value) |
Risk ratio | 95% CI |
|---|---|---|---|---|
| Sex (male vs. female) | 0.001 | 0.118 | – | – |
| Age (≥70 years) | < 0.001 | < 0.001 | 2.20 | 1.38–3.53 |
| PS (2 vs. 0–1) | 0.254 | – | – | – |
| Smoking | 0.005 | 0.183 | – | – |
| NLR(> 1.5) | 0.009 | 0.011 | 2.03 | 1.17–3.79 |
| Predicted post PFTa | 0.211 | – | – | – |
| Histology (other vs adenocarcinoma) | 0.123 | 0.090 | – | – |
| Differentiation (m/p vs. well) | 0.004 | 0.038 | 1.77 | 1.03–3.18 |
| Lymph-vascular invasion | < 0.001 | < 0.001 | 2.31 | 1.47–3.66 |
| Pathological stage (IB vs. IA) | < 0.001 | 0.003 | 2.09 | 1.27–3.48 |
| Postoperative complication | 0.368 | – | – | – |
| Preoperative comorbidities | ||||
| Hypertension | 0.846 | – | – | – |
| Diabetes mellitus | 0.797 | – | – | – |
| eGFR (< 70 mL/min/1.73 m2) | 0.107 | 0.647 | – | – |
| Child–Pugh classification (B or C) | 0.246 | – | – | – |
| Cardiac disease | 0.389 | – | – | – |
| Cerebral disease | 0.008 | 0.367 | – | – |
| Any prior tumors | 0.191 | 0.070 | – | – |
aPredicted postoperative values of FEV1.0 or DLCO < 40% is defined as high-risk for PFTs
PS performance status, NLR neutrophil-lymphocyte ratio, PFT pulmonary function test, m/p moderate or poor, eGFR estimated glomerular filtration rate